An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 486 participants.

Also called NCT07365332

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 486 participants (planned count) (from the registry)
Sponsor
Inhibikase Therapeutics (from the registry)
Registry
  • NCT NCT07365332
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Australia, Belgium, Canada, France, Germany, Italy, Netherlands, New Zealand, Portugal, South Korea, Spain, United Kingdom (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07365332. Randomized; quadruple masking; primary purpose treatment. Start 2026-04-23 (actual); primary completion 2029-06 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)
Acronym
IMPROVE-PAH
Condition
Pulmonary Arterial Hypertension
Intervention (Drug)
IKT-001
Intervention (Drug)
Placebo
Lead sponsor
Inhibikase Therapeutics (class: industry)

Record details

Record id
cardio:ct-nct07365332
Content hash
1cc4b0a46145e10f66f6a1aed72d4a92f42c7b29f920378c02aeddad22aa1fb8